Probability of Starting Two-Drug Regimen (2DR) Vs. Three-Drug Regimen (3DR) in ART-Naïve and ART-Experienced Person with HIV (PWH) Across the First Wave of COVID-19 Pandemic

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2025 Jan 8

PMID 39772133

Authors

Alessandra Vergori

Nicola Gianotti

Alessandro Tavelli

Camilla Tincati

Andrea Giacomelli

Elena Matteini

Giuseppe Lapadula

Lucia Taramasso

Loredana Sarmati

Antonella dArminio Monforte

Andrea Antinori

Alessandro Cozzi-Lepri

The Icona Foundation Study

Affiliations

Soon will be listed here.

Abstract

: This study examined the impact of the COVID-19 lockdown on antiretroviral therapy (ART) prescriptions among persons living with HIV (PWH) in Italy. : Data from the ICONA cohort included ART-naïve individuals who started ART between January 2019 and December 2022, and ART-experienced individuals who started new ART with HIV RNA ≤50 cps/mL from January 2016 to December 2022. The analysis focused on the proportion of PWH starting or switching to dual (2DR) versus triple (3DR) ART regimens. Comparisons were made using Chi-square and Kruskal-Wallis tests, with logistic regression (LR) to assess associations, adjusting for sex and age. : Among 2481 ART-naïve PWH, 17% were female, with a median age of 40. Using 2020 as the comparator (the lockdown year), the odds ratio (OR) from fitting a LR showed a reduced probability of prescribing 2DR both before and after 2020. The proportion of PWH starting 2DR was 9% in 2019, 18% in 2020, 13% in 2021, and 10% in 2022. Among 12,335 ART-experienced PWH, 20% were female, with a median age of 47. The proportion switching to 2DR rose from 24% in 2016 to 38% in 2020, 62% in 2021, and 65% in 2022, showing a >3-fold higher probability to be switched to 2DR instead of 3DR in recent years (2021-2022). : For ART-naive PWH, 2DR initiation did not decrease during the 2020 lockdown but changed in the following years, possibly indicating shifts in clinical practice or resuming HIV services. For ART-experienced PWH, 2DR prescriptions increased significantly over time, especially for INSTI-based regimens.

References

Kitahata M, Gange S, Abraham A, Merriman B, Saag M, Justice A . Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360(18):1815-26. PMC: 2854555. DOI: 10.1056/NEJMoa0807252. View

Aboud M, Orkin C, Podzamczer D, Bogner J, Baker D, Khuong-Josses M . Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019; 6(9):e576-e587. DOI: 10.1016/S2352-3018(19)30149-3. View

Lundgren J, Babiker A, Gordin F, Emery S, Grund B, Sharma S . Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015; 373(9):795-807. PMC: 4569751. DOI: 10.1056/NEJMoa1506816. View

Punekar Y, Parks D, Joshi M, Kaur S, Evitt L, Chounta V . Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence. HIV Med. 2021; 22(6):423-433. PMC: 8248313. DOI: 10.1111/hiv.13050. View

Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N . Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016; 375(9):830-9. PMC: 5049503. DOI: 10.1056/NEJMoa1600693. View

Waterfield K, Shah G, Etheredge G, Ikhile O . Consequences of COVID-19 crisis for persons with HIV: the impact of social determinants of health. BMC Public Health. 2021; 21(1):299. PMC: 7863613. DOI: 10.1186/s12889-021-10296-9. View

Meyer D, Slone S, Ogungbe O, Duroseau B, Farley J . Impact of the COVID-19 Pandemic on HIV Healthcare Service Engagement, Treatment Adherence, and Viral Suppression in the United States: A Systematic Literature Review. AIDS Behav. 2022; 27(1):344-357. PMC: 9344234. DOI: 10.1007/s10461-022-03771-w. View

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P . Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017; 390(10107):2063-2072. DOI: 10.1016/S0140-6736(17)32299-7. View

Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N . Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493-505. PMC: 3200068. DOI: 10.1056/NEJMoa1105243. View

10.

Llibre J, Brites C, Cheng C, Osiyemi O, Galera C, Hocqueloux L . Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the.... Clin Infect Dis. 2022; 76(4):720-729. PMC: 10021070. DOI: 10.1093/cid/ciac130. View

11.

Sax P, Pozniak A, Montes M, Koenig E, DeJesus E, Stellbrink H . Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3,.... Lancet. 2017; 390(10107):2073-2082. DOI: 10.1016/S0140-6736(17)32340-1. View

12.

Ridgway J, Schmitt J, Friedman E, Taylor M, Devlin S, McNulty M . HIV Care Continuum and COVID-19 Outcomes Among People Living with HIV During the COVID-19 Pandemic, Chicago, IL. AIDS Behav. 2020; 24(10):2770-2772. PMC: 7203502. DOI: 10.1007/s10461-020-02905-2. View

13.

Osiyemi O, De Wit S, Ajana F, Bisshop F, Portilla J, Routy J . Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week.... Clin Infect Dis. 2022; 75(6):975-986. PMC: 9639798. DOI: 10.1093/cid/ciac036. View